相关实验视频

Updated: Jul 17, 2026

In Vivo Modeling of the Morbid Human Genome using Danio rerio

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

通过系统的可使用药物的全基因组孟德尔随机化来识别盆腔器官脱落的新型疾病修饰剂

Xiaochun Liu¹, Zongyu Zhao², Lin Wang²

¹Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, 030032, People's Republic of China.

International journal of women's health

|October 15, 2025

概括

这项研究通过整合遗传数据来确定盆腔器官脱落 (POP) 的潜在药物标. 像ESR1和DES这样的关键基因显示出开发具有最小副作用的新型POP治疗方法的前景.

科学领域:

遗传学和生物信息学
药理学药理学是指药理学的学科.
妇女健康妇女健康

背景情况:

盆腔器官脱落 (POP) 是一个重大的全球健康挑战,治疗选择有限.
识别新型疾病修饰剂对于有效的POP治疗开发至关重要.

研究的目的:

为了确定盆腔器官脱落 (POP) 的潜在治疗点.
为开发针对POP的向治疗提供见解.

主要方法:

综合药物可用基因组数据,表达量化特征位点 (eQTL) 和全基因组关联研究 (GWAS).
采用孟德尔的随机化 (MR) 和局部化分析来确定治疗点.
进行功能丰富分析 (PPI网络,GO,KEGG) 和全现象MR (Phe-MR) 以评估目标相关性和安全性.

主要成果:

确定了23个阳性标和5个可用药物的基因,包括ESR1,DES和SLC12A2.2.
突出了与阴道发育和糖氨基结合有关的生物过程.
对于大多数已识别的基因,Phe-MR分析没有发现任何显著的不良影响,除了ESR1和DES.

结论:

这项研究确定了有希望的候选基因,用于未来在POP治疗中开发药物.
该研究阐明了POP潜在药物点的生物学作用,指导治疗策略.

关键词:

门德尔的随机化药物安全评估药物安全评估可以使用药物的基因组.丰富分析是一种丰富分析.骨盆器官脱落骨盆器官脱落一个全现象的关联研究研究.

更多相关视频

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations

Published on: December 1, 2017

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

相关概念视频

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...